Methods and compositions for treating melanoma
US-2024424002-A1 · Dec 26, 2024 · US
Method of optimizing the treatment of proliferative diseases mediated by the tyrosine kinase receptor KIT with imatinib
US9763944B2 · US · B2
| Field | Value |
|---|---|
| Publication number | US-9763944-B2 |
| Application number | US-201615297372-A |
| Country | US |
| Kind code | B2 |
| Filing date | Oct 19, 2016 |
| Priority date | Jan 23, 2008 |
| Publication date | Sep 19, 2017 |
| Grant date | Sep 19, 2017 |
How to read this patent
A practical reading order for non-experts. Skip the full description unless you need deep technical detail.
- Title
What the patent document calls the invention.
- Abstract
A short plain-language summary of the technical disclosure.
- Assignees and inventors
Who owns or filed the patent and who is credited as inventor.
- Key dates
Filing, priority, publication, and grant dates set the timeline.
- First independent claim
The legal scope of protection — read this for what is actually claimed.
- CPC / IPC classifications
Technology tags used to group this patent with similar filings.
- Citations and related patents
Prior art links and similar publications in this corpus.
Abstract
Official abstract text for this publication.
The invention relates to a method of treating proliferative diseases mediated by the tyrosine kinase receptor KIT, in particular GIST, in a human patient population.
First claim
Opening claim text (preview).
The invention claimed is: 1. A method of selectively treating a patient having unresectable/metastatic GIST harboring the Exon 11 KIT mutation, said method comprising: (a) administering a predetermined fixed dose of 400 mg or 600 mg of imatinib mesylate to the patient; (b) obtaining at least one blood sample from the patient within the first 12 months of treatment; (c) detecting a plasma trough level (Cmin) of less than 1100 ng/mL in the blood sample of the patient; and (d) thereafter selectively adjusting the dose of imatinib mesylate in a manner that maintains a Cmin of between 1100 and 2040 ng/mL of imatinib mesylate in the patient. 2. The method according to claim 1 wherein the at least one blood sample is collected within the first 3 months of treatment. 3. The method according to claim 1 wherein the at least one blood sample is collected within the first 30 days of treatment.
Assignees
Inventors
Classifications
specific for leukemia · CPC title
Antineoplastic agents · CPC title
specific for metastasis · CPC title
Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00 · CPC title
Drugs for disorders of the alimentary tract or the digestive system · CPC title
Patent family
Related publications grouped by family.
External sources
Frequently asked questions
Answers are generated from the same data shown on this page.
- What does patent US9763944B2 cover?
- The invention relates to a method of treating proliferative diseases mediated by the tyrosine kinase receptor KIT, in particular GIST, in a human patient population.
- Who is the assignee on this patent?
- Wang Yanfeng, Wehrle Elisabeth, Novartis Ag
- What technology area does this patent fall under?
- Primary CPC classification A61K31/506. Mapped technology areas include Human Necessities.
- When was this patent published?
- Publication date Tue Sep 19 2017 00:00:00 GMT+0000 (Coordinated Universal Time) (B2). Legal status and post-grant events are not shown on this page.
- What related patents are in patentsdb?
- We list 8 related publications on this page (citations in our corpus or others sharing the same primary CPC).